P180 A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)

Autor:	S.D. Moodley, Bernardo Leon Rapoport, R. Pienaar, W.M. Szpak, S. Fourie, C. Jacobs
Rok vydání:	2007
Předmět:	Oncology medicine.medical_specialty Cyclophosphamide Adjuvant chemotherapy business.industry Node (networking) General Medicine Cost-effectiveness analysis Fluorouracil Internal medicine Docetaxel/doxorubicin medicine Surgery Doxorubicin business medicine.drug Early breast cancer
Zdroj:	The Breast. 16:S64
ISSN:	0960-9776
DOI:	10.1016/s0960-9776(07)70240-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d26947aa42d9644093b74211e33af761 https://doi.org/10.1016/s0960-9776(07)70240-0 Zobrazit plný text záznamu Full Text from ScienceDirect